News about "Piramal Pharma"

Piramal Pharma Solutions Commercialises Tablet-in-Capsule Technology at Indian Manufacturing Sites

Piramal Pharma Solutions has successfully developed and commercialised a tablet-in-capsule drug delivery system in India, enabling flexible dosing, dual-release profiles and improved patient-centric oral therapies.

Piramal Pharma | 03/02/2026 | By News Bureau |  122

Piramal Pharma Acquires Global Rights to Kenalog Brand in Up to USD 100 Million Deal

Piramal Pharma has agreed to acquire the global rights to the Kenalog brand and its associated injectable corticosteroid products from Bristol-Myers Squibb in a deal valued at up to USD 100 million. The acquisition will be executed through Piramal’s wholly owned subsidiary, Piramal Critical Care B.V.

Piramal Pharma | 02/02/2026 | By Darshana |  144

Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK

Piramal Pharma Solutions leveraged its CDMO expertise to help George Medicines develop WIDAPLIK, the first and only FDA-approved triple combination therapy for hypertension, combining telmisartan, amlodipine, and indapamide to effectively lower blood pressure.

Piramal Pharma | 01/09/2025 | By Mrinmoy Dey |  164

Piramal Pharma to Operate its Digwal Facility on Biomass Briquettes to Promote Sustainability

This achievement marks a substantial step toward Piramal's sustainability goal to reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 42 percent by 2030.

Piramal Pharma | 16/01/2025 | By Aishwarya |  758

Piramal Pharma Gets SBTi Approval for its GHG Emission Reduction Targets

Piramal Pharma Ltd. has committed to reduce absolute scope 1 and 2 GHG emissions 42 percent by FY2030 from a FY2022 base year.

Piramal Pharma | 17/09/2024 | By Aishwarya |  470

Piramal Pharma Gets EIR from US FDA for Bethlehem Plant

The EIR report signifies the closure of the inspection.

Piramal Pharma | 10/11/2023 | By Manvi |  912

Piramal Pharma gets EIR from US FDA for Sellersville, USA facility

The inspection has now been successfully closed by the US FDA

Piramal Pharma | 19/04/2023 | By Sudeep Soparkar |  876

Piramal Pharma gets EIR for Lexington, Kentucky facility

The inspection has been successfully completed<br />

Piramal Pharma | 20/02/2023 | By Sudeep Soparkar |  686

Piramal Pharma's Lexington facility gets six observations from US FDA

The observations were classified under VAI (Voluntary Action Indicated) and do not relate to data integrity<br />

Piramal Pharma | 17/01/2023 | By Sudeep Soparkar |  480

Piramal Pharma gets zero observations from US FDA for Riverview, Michigan facility

The inspection was completed successfully with Zero Form - 483 observations

Piramal Pharma | 11/11/2022 | By Sudeep Soparkar |  1061